Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07123441) titled 'A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer' on Aug. 1.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Sanjun Cai
Condition:
Colorectal Cancer
Intervention:
Drug: Bevacizumab,Irinotecan liposome (II),5-FU/LV
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 1, 2025
Target Sample Size: 300
Countries of Recruitment:
China
To know more,...